AC Immune SA (FRA:IMR)

Market Cap	265.66M +3.1%
Revenue (ttm)	4.67M -89.3%
Net Income	-76.82M
EPS	-0.77
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	482
Open	2.890
Previous Close	2.875
Day's Range	2.890 - 2.890
52-Week Range	1.244 - 3.315
Beta	n/a
RSI	46.43
Earnings Date	Mar 13, 2026

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 172
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IMR

Financial Performance

In 2024, AC Immune's revenue was 27.31 million, an increase of 84.51% compared to the previous year's 14.80 million. Losses were -50.92 million, -6.12% less than in 2023.

Financial numbers in CHF